Travere Therapeutics, Inc. Common Stock (TVTX) Financials
Key financial figures for Travere Therapeutics, Inc. Common Stock (Q3 2026).
FILSPARI net product sales rose 120% year over year to $200.2M and total revenue reached $224.6M, but a $113.1M in-process R&D charge for the civorebrutinib license produced a GAAP net loss of $52.3M. Total revenue was $224.6M versus $164.9M a year earlier (+36%, calculated); total U.S. net product sales were $220.2M versus $113.2M. FILSPARI net product sales were $200.2M versus $90.9M (+120%), and 1,932 new patient start forms were received. GAAP operating loss was $68.1M versus operating income of $24.9M a year earlier, driven by a $113.1M in-process R&D expense when the Everest Medicines civorebrutinib license closed. R&D was $70.3M (vs $51.9M) and SG&A was $98.4M (vs $71.0M). Figures are for Q3 2026, as Travere Therapeutics Inc. reported them.
- Revenue
- $225M
- Net Income
- -$52M
- EPS
- $-0.55
- Total Assets
- $848M
- Operating Cash Flow
- $98M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $225M | -$52M | -$0.55 | -30.33% | $98M |
| Q2 FY2026 | $170M | -$35M | -$0.37 | 2.33% | $58M |
| Q1 FY2026 | $127M | -$37M | -$0.40 | -29.02% | -$63M |
| Q4 FY2025 | $130M | $3M | -$0.24 | -25% | $42M |
| Q3 FY2025 | $165M | $26M | $0.28 | 15.12% | $14M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $491M | -$26M | -$0.29 | -12.8% | -$20M |
| FY2024 | $233M | -$322M | -$4.08 | -138.88% | -$339M |
| FY2023 | $145M | -$111M | -$1.50 | -267.24% | -$322M |
Frequently asked questions
What was Travere Therapeutics Inc.'s revenue last quarter?
Travere Therapeutics Inc. reported revenue of $224.6 million for Q3 FY2026, up 36.2% from the same period a year earlier.
Is Travere Therapeutics Inc. profitable?
Not in its most recent reported period. Travere Therapeutics Inc. reported a net loss of $52.3 million for Q3 FY2026, a net margin of -23.31% on revenue.
How has Travere Therapeutics Inc.'s margin trended?
Operating margin was -30.33% in Q3 FY2026, compared with 15.12% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Travere Therapeutics Inc. generate?
Travere Therapeutics Inc. generated free cash flow of $98.2 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Travere Therapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.